*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2025 | Emerging pharmacotherapies for obesity: A systematic review Pharmacological reviews · preclinical | PMID 39952695 |
| 2024 | A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis The New England journal of medicine · human | PMID 38847460 |
| 2024 | Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial The lancet. Diabetes & endocrinology · human | PMID 38330987 |
| 2024 | Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity Diabetes care · preclinical | PMID 38843460 |
| 2024 | Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial Diabetologia · human | PMID 38095657 |
| 2024 | Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis Journal of hepatology · human | PMID 38857788 |
| 2024 | The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation Metabolism: clinical and experimental · preclinical | PMID 39481534 |
| 2024 | Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial JACC. Heart failure · preclinical | PMID 39453356 |
Survodutide (Survodutide (GLP-1/glucagon dual agonist)). Dual agonist of glucagon and GLP-1 receptors; investigated for obesity and MASH (metabolic dysfunction-associated steatohepatitis).
Commonly discussed uses: investigational obesity and MASH (trials). There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Dual agonist of glucagon and GLP-1 receptors; investigated for obesity and MASH (metabolic dysfunction-associated steatohepatitis).
Reported considerations: GI: nausea, vomiting (dose-related), long-term safety under study. There is both human and animal/preclinical research, though the depth and quality vary by indication. Investigational. Not approved. Grey-market sale is unverified material. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low trial titration, typical investigational, high trial-defined. Administration: subcutaneous. Half-life: long-acting (weekly dosing in trials).
Australian status: Investigational — not approved. Investigational. Not approved. Grey-market sale is unverified material. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: research vials vary; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): investigational monotherapy. Stacking increases interaction/safety uncertainty.